Quaternary ammonium compound-based ionic liquid with microwave responsiveness for treating deep tissue infections without compromising biocompatibility

IF 10.4 1区 医学 Q1 ENGINEERING, BIOMEDICAL
Acta Biomaterialia Pub Date : 2026-10-01 Epub Date: 2026-08-15 DOI:10.1016/j.actbio.2026.08.024
Zexiang Li, Linpeng Liu, Yan Song, Zhizheng Zhou, Lu Zhou, Xinyu Cai, Liangjv Duan, Yanhong Dong, Jie Zhao, Lingwan Hao, Jingting Wang, Rujian Jiang
{"title":"Quaternary ammonium compound-based ionic liquid with microwave responsiveness for treating deep tissue infections without compromising biocompatibility","authors":"Zexiang Li,&nbsp;Linpeng Liu,&nbsp;Yan Song,&nbsp;Zhizheng Zhou,&nbsp;Lu Zhou,&nbsp;Xinyu Cai,&nbsp;Liangjv Duan,&nbsp;Yanhong Dong,&nbsp;Jie Zhao,&nbsp;Lingwan Hao,&nbsp;Jingting Wang,&nbsp;Rujian Jiang","doi":"10.1016/j.actbio.2026.08.024","DOIUrl":null,"url":null,"abstract":"<div><div>Quaternary ammonium compounds (QACs) hold great promise as alternatives to conventional antibiotics due to their broad-spectrum antibacterial activity and minimal propensity for inducing bacterial drug resistance. However, their inherent cytotoxicity and pro-inflammatory property perpetuate an intractable efficacy-biocompatibility trade-off, severely limiting clinical translation. Herein, aimed to solve this dilemma, we developed a microwave-responsive ionic liquid (IL) via the integration of QACs with an anti-inflammatory anionic organic compound, enabling synergistic bactericidal efficacy through microwave-induced hyperthermia while concomitantly alleviating QAC-related toxicity and inflammation. After loading into bacteria-targeted hollow polydopamine nanoparticles (HPDA NPs), this IL-based nanoplatform exhibited selective biocidal discrimination between bacterial and mammalian cells, fundamentally mitigating QAC-related cytotoxicity. Notably, embedding these nanoparticles into poly (vinyl pyrrolidone) MNs (IL@HPDA@MN) achieved up to 99.8% bactericidal efficiency coupled with robust anti-inflammatory effects in a mouse subcutaneous abscess model, leading to accelerated abscess resolution and tissue regeneration that outperformed clinical antibiotics. Beyond resolving the QAC-centric efficacy-biocompatibility paradox, this work provides a generalizable framework for engineering toxic cationic antibacterial agents into biocompatible, targeted therapeutics, offering a transformative approach for treating deep-seated bacterial infections that are refractory to traditional therapies.</div></div><div><h3>Statement of significance</h3><div>Quaternary ammonium compounds (QACs) are promising alternatives to conventional antibiotics due to their broad-spectrum activity and low resistance risk. Yet, their clinical adoption remains paralyzed by an inherent trade-off between bactericidal efficacy and unacceptable cytotoxicity, pro-inflammation. Here, we break this deadlock by rationally integrating a QAC with an anti‑inflammatory organic compound to form a microwave-responsive ionic liquid (IL). When encapsulated in bacteria-targeted hollow polydopamine nanoparticles and further loaded into a dissolvable microneedle patch, this IL-based platform achieves potent bacterial killing under mild microwave irradiation while exhibiting negligible toxicity toward mammalian cells. In a murine subcutaneous abscess model, the system rapidly resolves deep-seated infections and curtails local inflammation, achieving therapeutic outcomes that rival or surpass those of clinical antibiotics. Beyond offering a ready-to-use strategy for treating refractory deep-tissue infections, this work establishes a generalizable paradigm for converting toxic cationic antimicrobials into biocompatible, spatially controllable therapeutics.</div></div>","PeriodicalId":237,"journal":{"name":"Acta Biomaterialia","volume":"223 ","pages":"Pages 421-436"},"PeriodicalIF":10.4000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Biomaterialia","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1742706126005556","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Quaternary ammonium compounds (QACs) hold great promise as alternatives to conventional antibiotics due to their broad-spectrum antibacterial activity and minimal propensity for inducing bacterial drug resistance. However, their inherent cytotoxicity and pro-inflammatory property perpetuate an intractable efficacy-biocompatibility trade-off, severely limiting clinical translation. Herein, aimed to solve this dilemma, we developed a microwave-responsive ionic liquid (IL) via the integration of QACs with an anti-inflammatory anionic organic compound, enabling synergistic bactericidal efficacy through microwave-induced hyperthermia while concomitantly alleviating QAC-related toxicity and inflammation. After loading into bacteria-targeted hollow polydopamine nanoparticles (HPDA NPs), this IL-based nanoplatform exhibited selective biocidal discrimination between bacterial and mammalian cells, fundamentally mitigating QAC-related cytotoxicity. Notably, embedding these nanoparticles into poly (vinyl pyrrolidone) MNs (IL@HPDA@MN) achieved up to 99.8% bactericidal efficiency coupled with robust anti-inflammatory effects in a mouse subcutaneous abscess model, leading to accelerated abscess resolution and tissue regeneration that outperformed clinical antibiotics. Beyond resolving the QAC-centric efficacy-biocompatibility paradox, this work provides a generalizable framework for engineering toxic cationic antibacterial agents into biocompatible, targeted therapeutics, offering a transformative approach for treating deep-seated bacterial infections that are refractory to traditional therapies.

Statement of significance

Quaternary ammonium compounds (QACs) are promising alternatives to conventional antibiotics due to their broad-spectrum activity and low resistance risk. Yet, their clinical adoption remains paralyzed by an inherent trade-off between bactericidal efficacy and unacceptable cytotoxicity, pro-inflammation. Here, we break this deadlock by rationally integrating a QAC with an anti‑inflammatory organic compound to form a microwave-responsive ionic liquid (IL). When encapsulated in bacteria-targeted hollow polydopamine nanoparticles and further loaded into a dissolvable microneedle patch, this IL-based platform achieves potent bacterial killing under mild microwave irradiation while exhibiting negligible toxicity toward mammalian cells. In a murine subcutaneous abscess model, the system rapidly resolves deep-seated infections and curtails local inflammation, achieving therapeutic outcomes that rival or surpass those of clinical antibiotics. Beyond offering a ready-to-use strategy for treating refractory deep-tissue infections, this work establishes a generalizable paradigm for converting toxic cationic antimicrobials into biocompatible, spatially controllable therapeutics.
具有微波响应性的季铵盐离子液体在不影响生物相容性的情况下治疗深部组织感染。
季铵类化合物(QACs)具有广谱抗菌活性和极小的诱导细菌耐药倾向,因此作为传统抗生素的替代品具有很大的前景。然而,它们固有的细胞毒性和促炎特性使得难以解决的疗效与生物相容性之间的权衡,严重限制了临床转化。为了解决这一难题,我们开发了一种微波响应离子液体(IL),通过QACs与抗炎阴离子有机化合物的整合,通过微波诱导的热疗法实现协同杀菌效果,同时减轻qac相关的毒性和炎症。在装载到细菌靶向的中空聚多巴胺纳米颗粒(HPDA NPs)后,这种基于il的纳米平台在细菌和哺乳动物细胞之间表现出选择性的生物杀灭能力,从根本上减轻了qac相关的细胞毒性。值得注意的是,在小鼠皮下脓肿模型中,将这些纳米颗粒嵌入聚(乙烯基吡咯烷酮)mnns (IL@HPDA@MN)中,杀菌效率高达99.8%,并具有强大的抗炎作用,导致脓肿溶解和组织再生加速,优于临床抗生素。除了解决以qac为中心的疗效-生物相容性悖论之外,这项工作还为将有毒阳离子抗菌剂改造成生物相容性靶向治疗药物提供了一个可推广的框架,为治疗传统疗法难以治愈的深层细菌感染提供了一种变革性的方法。重要意义:季铵化合物(QACs)由于其广谱活性和低耐药风险,是传统抗生素的有希望的替代品。然而,它们的临床应用仍然瘫痪的内在权衡之间的杀菌功效和不可接受的细胞毒性,促炎症。在这里,我们通过将QAC与抗炎有机化合物合理整合形成微波响应离子液体(IL)来打破这一僵局。当包裹在细菌靶向的中空聚多巴胺纳米颗粒中,并进一步装入可溶解的微针贴片时,这种基于il的平台在温和的微波照射下实现了有效的细菌杀伤,同时对哺乳动物细胞的毒性可以忽略不计。在小鼠皮下脓肿模型中,该系统迅速解决了深层感染并减少了局部炎症,达到了与临床抗生素相媲美或超过的治疗效果。除了提供一种治疗难治性深层组织感染的即用型策略外,这项工作还建立了一种可推广的范例,将有毒阳离子抗菌剂转化为生物相容性、空间可控的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Biomaterialia
Acta Biomaterialia 工程技术-材料科学:生物材料
CiteScore
16.80
自引率
3.10%
发文量
776
审稿时长
30 days
期刊介绍: Acta Biomaterialia is a monthly peer-reviewed scientific journal published by Elsevier. The journal was established in January 2005. The editor-in-chief is W.R. Wagner (University of Pittsburgh). The journal covers research in biomaterials science, including the interrelationship of biomaterial structure and function from macroscale to nanoscale. Topical coverage includes biomedical and biocompatible materials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书